The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer
PARTNER is a prospective, phase II–III, randomized controlled clinical trial that recruited patients with triple-negative breast cancer 1 , 2 , who were germline BRCA 1 and BRCA2 wild type 3 . Here we report the results of the trial. Patients ( n = 559) were randomized on a 1:1 basis to receive ne...
Gespeichert in:
| Veröffentlicht in: | Nature (London) 2024-05, Vol.629 (8014), p.1142-1148 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1148 |
|---|---|
| container_issue | 8014 |
| container_start_page | 1142 |
| container_title | Nature (London) |
| container_volume | 629 |
| creator | Abraham, Jean E. Pinilla, Karen Dayimu, Alimu Grybowicz, Louise Demiris, Nikolaos Harvey, Caron Drewett, Lynsey M. Lucey, Rebecca Fulton, Alexander Roberts, Anne N. Worley, Joanna R. Chhabra, Anita Qian, Wendi Vallier, Anne-Laure Hardy, Richard M. Chan, Steve Hickish, Tamas Tripathi, Devashish Venkitaraman, Ramachandran Persic, Mojca Aslam, Shahzeena Glassman, Daniel Raj, Sanjay Borley, Annabel Braybrooke, Jeremy P. Sutherland, Stephanie Staples, Emma Scott, Lucy C. Davies, Mark Palmer, Cheryl A. Moody, Margaret Churn, Mark J. Newby, Jacqueline C. Mukesh, Mukesh B. Chakrabarti, Amitabha Roylance, Rebecca R. Schouten, Philip C. Levitt, Nicola C. McAdam, Karen Armstrong, Anne C. Copson, Ellen R. McMurtry, Emma Tischkowitz, Marc Provenzano, Elena Earl, Helena M. |
| description | PARTNER is a prospective, phase II–III, randomized controlled clinical trial that recruited patients with triple-negative breast cancer
1
,
2
, who were germline
BRCA
1
and
BRCA2
wild type
3
. Here we report the results of the trial. Patients (
n
= 559) were randomized on a 1:1 basis to receive neoadjuvant carboplatin–paclitaxel with or without 150 mg olaparib twice daily, on days 3 to 14, of each of four cycles (gap schedule olaparib, research arm) followed by three cycles of anthracycline-based chemotherapy before surgery. The primary end point was pathologic complete response (pCR)
4
, and secondary end points included event-free survival (EFS) and overall survival (OS)
5
. pCR was achieved in 51% of patients in the research arm and 52% in the control arm (
P
= 0.753). Estimated EFS at 36 months in the research and control arms was 80% and 79% (log-rank
P
> 0.9), respectively; OS was 90% and 87.2% (log-rank
P
= 0.8), respectively. In patients with pCR, estimated EFS at 36 months was 90%, and in those with non-pCR it was 70% (log-rank
P
|
| doi_str_mv | 10.1038/s41586-024-07384-2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11136660</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3035075304</sourcerecordid><originalsourceid>FETCH-LOGICAL-c426t-6bbd32eb8681ac11d1ed6d5916f830404fcd1869b7be395a763e356a4d6a9f2e3</originalsourceid><addsrcrecordid>eNp9kc1u1DAUhS0EotPCC7BAlth0Y7Bjx3ZWqKpKQaoAVcMSWU5yM_EoYwfbGdS34Vl4MlymlJ8FKy_ud47PvQehZ4y-ZJTrV0mwWktCK0Go4lqQ6gFaMaEkEVKrh2hFaaUJ1VweoeOUtpTSminxGB1xXWstG7lCn9cj4I9n1-v3F9c4R2cnHAbsIdh-u-ytzzhMdrbRtfiryyPuRtiFPEK08833b87fauYJiIeNzW4PuI1gU8ad9R3EJ-jRYKcET-_eE_TpzcX6_C25-nD57vzsinSikpnItu15Ba2WmtmOsZ5BL_u6YXLQnAoqhq5nJW-rWuBNbZXkwGtpRS9tM1TAT9Drg--8tDvoO_A52snM0e1svDHBOvP3xLvRbMLeMMa4lJIWh9M7hxi-LJCy2bnUwTTZcoslGU55TVVd0hT0xT_oNizRl_0KJblqtFa8UNWB6mJIKcJwn4ZRc1ufOdRnSn3mZ32mKqLnf-5xL_nVVwH4AUhl5DcQf__9H9sf7D6nkg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3063798873</pqid></control><display><type>article</type><title>The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer</title><source>MEDLINE</source><source>SpringerLink Journals</source><source>Nature Journals Online</source><creator>Abraham, Jean E. ; Pinilla, Karen ; Dayimu, Alimu ; Grybowicz, Louise ; Demiris, Nikolaos ; Harvey, Caron ; Drewett, Lynsey M. ; Lucey, Rebecca ; Fulton, Alexander ; Roberts, Anne N. ; Worley, Joanna R. ; Chhabra, Anita ; Qian, Wendi ; Vallier, Anne-Laure ; Hardy, Richard M. ; Chan, Steve ; Hickish, Tamas ; Tripathi, Devashish ; Venkitaraman, Ramachandran ; Persic, Mojca ; Aslam, Shahzeena ; Glassman, Daniel ; Raj, Sanjay ; Borley, Annabel ; Braybrooke, Jeremy P. ; Sutherland, Stephanie ; Staples, Emma ; Scott, Lucy C. ; Davies, Mark ; Palmer, Cheryl A. ; Moody, Margaret ; Churn, Mark J. ; Newby, Jacqueline C. ; Mukesh, Mukesh B. ; Chakrabarti, Amitabha ; Roylance, Rebecca R. ; Schouten, Philip C. ; Levitt, Nicola C. ; McAdam, Karen ; Armstrong, Anne C. ; Copson, Ellen R. ; McMurtry, Emma ; Tischkowitz, Marc ; Provenzano, Elena ; Earl, Helena M.</creator><creatorcontrib>Abraham, Jean E. ; Pinilla, Karen ; Dayimu, Alimu ; Grybowicz, Louise ; Demiris, Nikolaos ; Harvey, Caron ; Drewett, Lynsey M. ; Lucey, Rebecca ; Fulton, Alexander ; Roberts, Anne N. ; Worley, Joanna R. ; Chhabra, Anita ; Qian, Wendi ; Vallier, Anne-Laure ; Hardy, Richard M. ; Chan, Steve ; Hickish, Tamas ; Tripathi, Devashish ; Venkitaraman, Ramachandran ; Persic, Mojca ; Aslam, Shahzeena ; Glassman, Daniel ; Raj, Sanjay ; Borley, Annabel ; Braybrooke, Jeremy P. ; Sutherland, Stephanie ; Staples, Emma ; Scott, Lucy C. ; Davies, Mark ; Palmer, Cheryl A. ; Moody, Margaret ; Churn, Mark J. ; Newby, Jacqueline C. ; Mukesh, Mukesh B. ; Chakrabarti, Amitabha ; Roylance, Rebecca R. ; Schouten, Philip C. ; Levitt, Nicola C. ; McAdam, Karen ; Armstrong, Anne C. ; Copson, Ellen R. ; McMurtry, Emma ; Tischkowitz, Marc ; Provenzano, Elena ; Earl, Helena M.</creatorcontrib><description>PARTNER is a prospective, phase II–III, randomized controlled clinical trial that recruited patients with triple-negative breast cancer
1
,
2
, who were germline
BRCA
1
and
BRCA2
wild type
3
. Here we report the results of the trial. Patients (
n
= 559) were randomized on a 1:1 basis to receive neoadjuvant carboplatin–paclitaxel with or without 150 mg olaparib twice daily, on days 3 to 14, of each of four cycles (gap schedule olaparib, research arm) followed by three cycles of anthracycline-based chemotherapy before surgery. The primary end point was pathologic complete response (pCR)
4
, and secondary end points included event-free survival (EFS) and overall survival (OS)
5
. pCR was achieved in 51% of patients in the research arm and 52% in the control arm (
P
= 0.753). Estimated EFS at 36 months in the research and control arms was 80% and 79% (log-rank
P
> 0.9), respectively; OS was 90% and 87.2% (log-rank
P
= 0.8), respectively. In patients with pCR, estimated EFS at 36 months was 90%, and in those with non-pCR it was 70% (log-rank
P
< 0.001), and OS was 96% and 83% (log-rank
P
< 0.001), respectively. Neoadjuvant olaparib did not improve pCR rates, EFS or OS when added to carboplatin–paclitaxel and anthracycline-based chemotherapy in patients with triple-negative breast cancer who were germline
BRCA1
and
BRCA2
wild type. ClinicalTrials.gov ID:
NCT03150576
.
A study details the results of the PARTNER trial, a prospective, randomized controlled trial of the use of neoadjuvant olaparib with carboplatin–paclitaxel chemotherapy in patients with triple-negative breast cancer who were germline
BRCA1
and
BRCA2
wild type.</description><identifier>ISSN: 0028-0836</identifier><identifier>ISSN: 1476-4687</identifier><identifier>EISSN: 1476-4687</identifier><identifier>DOI: 10.1038/s41586-024-07384-2</identifier><identifier>PMID: 38588696</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/67/1059/602 ; 631/67/1059/99 ; 631/67/1347 ; Adult ; Aged ; Anthracycline ; Anthracyclines - administration & dosage ; Anthracyclines - therapeutic use ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; BRCA1 protein ; BRCA1 Protein - genetics ; BRCA1 Protein - metabolism ; BRCA2 protein ; BRCA2 Protein - genetics ; Breast cancer ; Carboplatin ; Carboplatin - administration & dosage ; Carboplatin - therapeutic use ; Chemotherapy ; Female ; Germ-Line Mutation ; Humanities and Social Sciences ; Humans ; Middle Aged ; multidisciplinary ; Neoadjuvant Therapy ; Ovarian cancer ; Paclitaxel ; Paclitaxel - administration & dosage ; Patients ; Phthalazines - administration & dosage ; Phthalazines - therapeutic use ; Piperazines - administration & dosage ; Piperazines - therapeutic use ; Prospective Studies ; Science ; Science (multidisciplinary) ; Surgery ; Survival ; Triple Negative Breast Neoplasms - drug therapy ; Triple Negative Breast Neoplasms - pathology ; Tumors</subject><ispartof>Nature (London), 2024-05, Vol.629 (8014), p.1142-1148</ispartof><rights>The Author(s) 2024</rights><rights>2024. The Author(s).</rights><rights>Copyright Nature Publishing Group May 30, 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c426t-6bbd32eb8681ac11d1ed6d5916f830404fcd1869b7be395a763e356a4d6a9f2e3</cites><orcidid>0000-0003-0688-4807 ; 0000-0002-2723-0805 ; 0000-0002-6226-447X ; 0000-0002-7880-0628 ; 0000-0002-9899-8010 ; 0000-0002-4238-3471</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/s41586-024-07384-2$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/s41586-024-07384-2$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38588696$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Abraham, Jean E.</creatorcontrib><creatorcontrib>Pinilla, Karen</creatorcontrib><creatorcontrib>Dayimu, Alimu</creatorcontrib><creatorcontrib>Grybowicz, Louise</creatorcontrib><creatorcontrib>Demiris, Nikolaos</creatorcontrib><creatorcontrib>Harvey, Caron</creatorcontrib><creatorcontrib>Drewett, Lynsey M.</creatorcontrib><creatorcontrib>Lucey, Rebecca</creatorcontrib><creatorcontrib>Fulton, Alexander</creatorcontrib><creatorcontrib>Roberts, Anne N.</creatorcontrib><creatorcontrib>Worley, Joanna R.</creatorcontrib><creatorcontrib>Chhabra, Anita</creatorcontrib><creatorcontrib>Qian, Wendi</creatorcontrib><creatorcontrib>Vallier, Anne-Laure</creatorcontrib><creatorcontrib>Hardy, Richard M.</creatorcontrib><creatorcontrib>Chan, Steve</creatorcontrib><creatorcontrib>Hickish, Tamas</creatorcontrib><creatorcontrib>Tripathi, Devashish</creatorcontrib><creatorcontrib>Venkitaraman, Ramachandran</creatorcontrib><creatorcontrib>Persic, Mojca</creatorcontrib><creatorcontrib>Aslam, Shahzeena</creatorcontrib><creatorcontrib>Glassman, Daniel</creatorcontrib><creatorcontrib>Raj, Sanjay</creatorcontrib><creatorcontrib>Borley, Annabel</creatorcontrib><creatorcontrib>Braybrooke, Jeremy P.</creatorcontrib><creatorcontrib>Sutherland, Stephanie</creatorcontrib><creatorcontrib>Staples, Emma</creatorcontrib><creatorcontrib>Scott, Lucy C.</creatorcontrib><creatorcontrib>Davies, Mark</creatorcontrib><creatorcontrib>Palmer, Cheryl A.</creatorcontrib><creatorcontrib>Moody, Margaret</creatorcontrib><creatorcontrib>Churn, Mark J.</creatorcontrib><creatorcontrib>Newby, Jacqueline C.</creatorcontrib><creatorcontrib>Mukesh, Mukesh B.</creatorcontrib><creatorcontrib>Chakrabarti, Amitabha</creatorcontrib><creatorcontrib>Roylance, Rebecca R.</creatorcontrib><creatorcontrib>Schouten, Philip C.</creatorcontrib><creatorcontrib>Levitt, Nicola C.</creatorcontrib><creatorcontrib>McAdam, Karen</creatorcontrib><creatorcontrib>Armstrong, Anne C.</creatorcontrib><creatorcontrib>Copson, Ellen R.</creatorcontrib><creatorcontrib>McMurtry, Emma</creatorcontrib><creatorcontrib>Tischkowitz, Marc</creatorcontrib><creatorcontrib>Provenzano, Elena</creatorcontrib><creatorcontrib>Earl, Helena M.</creatorcontrib><title>The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer</title><title>Nature (London)</title><addtitle>Nature</addtitle><addtitle>Nature</addtitle><description>PARTNER is a prospective, phase II–III, randomized controlled clinical trial that recruited patients with triple-negative breast cancer
1
,
2
, who were germline
BRCA
1
and
BRCA2
wild type
3
. Here we report the results of the trial. Patients (
n
= 559) were randomized on a 1:1 basis to receive neoadjuvant carboplatin–paclitaxel with or without 150 mg olaparib twice daily, on days 3 to 14, of each of four cycles (gap schedule olaparib, research arm) followed by three cycles of anthracycline-based chemotherapy before surgery. The primary end point was pathologic complete response (pCR)
4
, and secondary end points included event-free survival (EFS) and overall survival (OS)
5
. pCR was achieved in 51% of patients in the research arm and 52% in the control arm (
P
= 0.753). Estimated EFS at 36 months in the research and control arms was 80% and 79% (log-rank
P
> 0.9), respectively; OS was 90% and 87.2% (log-rank
P
= 0.8), respectively. In patients with pCR, estimated EFS at 36 months was 90%, and in those with non-pCR it was 70% (log-rank
P
< 0.001), and OS was 96% and 83% (log-rank
P
< 0.001), respectively. Neoadjuvant olaparib did not improve pCR rates, EFS or OS when added to carboplatin–paclitaxel and anthracycline-based chemotherapy in patients with triple-negative breast cancer who were germline
BRCA1
and
BRCA2
wild type. ClinicalTrials.gov ID:
NCT03150576
.
A study details the results of the PARTNER trial, a prospective, randomized controlled trial of the use of neoadjuvant olaparib with carboplatin–paclitaxel chemotherapy in patients with triple-negative breast cancer who were germline
BRCA1
and
BRCA2
wild type.</description><subject>631/67/1059/602</subject><subject>631/67/1059/99</subject><subject>631/67/1347</subject><subject>Adult</subject><subject>Aged</subject><subject>Anthracycline</subject><subject>Anthracyclines - administration & dosage</subject><subject>Anthracyclines - therapeutic use</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>BRCA1 protein</subject><subject>BRCA1 Protein - genetics</subject><subject>BRCA1 Protein - metabolism</subject><subject>BRCA2 protein</subject><subject>BRCA2 Protein - genetics</subject><subject>Breast cancer</subject><subject>Carboplatin</subject><subject>Carboplatin - administration & dosage</subject><subject>Carboplatin - therapeutic use</subject><subject>Chemotherapy</subject><subject>Female</subject><subject>Germ-Line Mutation</subject><subject>Humanities and Social Sciences</subject><subject>Humans</subject><subject>Middle Aged</subject><subject>multidisciplinary</subject><subject>Neoadjuvant Therapy</subject><subject>Ovarian cancer</subject><subject>Paclitaxel</subject><subject>Paclitaxel - administration & dosage</subject><subject>Patients</subject><subject>Phthalazines - administration & dosage</subject><subject>Phthalazines - therapeutic use</subject><subject>Piperazines - administration & dosage</subject><subject>Piperazines - therapeutic use</subject><subject>Prospective Studies</subject><subject>Science</subject><subject>Science (multidisciplinary)</subject><subject>Surgery</subject><subject>Survival</subject><subject>Triple Negative Breast Neoplasms - drug therapy</subject><subject>Triple Negative Breast Neoplasms - pathology</subject><subject>Tumors</subject><issn>0028-0836</issn><issn>1476-4687</issn><issn>1476-4687</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><recordid>eNp9kc1u1DAUhS0EotPCC7BAlth0Y7Bjx3ZWqKpKQaoAVcMSWU5yM_EoYwfbGdS34Vl4MlymlJ8FKy_ud47PvQehZ4y-ZJTrV0mwWktCK0Go4lqQ6gFaMaEkEVKrh2hFaaUJ1VweoeOUtpTSminxGB1xXWstG7lCn9cj4I9n1-v3F9c4R2cnHAbsIdh-u-ytzzhMdrbRtfiryyPuRtiFPEK08833b87fauYJiIeNzW4PuI1gU8ad9R3EJ-jRYKcET-_eE_TpzcX6_C25-nD57vzsinSikpnItu15Ba2WmtmOsZ5BL_u6YXLQnAoqhq5nJW-rWuBNbZXkwGtpRS9tM1TAT9Drg--8tDvoO_A52snM0e1svDHBOvP3xLvRbMLeMMa4lJIWh9M7hxi-LJCy2bnUwTTZcoslGU55TVVd0hT0xT_oNizRl_0KJblqtFa8UNWB6mJIKcJwn4ZRc1ufOdRnSn3mZ32mKqLnf-5xL_nVVwH4AUhl5DcQf__9H9sf7D6nkg</recordid><startdate>20240530</startdate><enddate>20240530</enddate><creator>Abraham, Jean E.</creator><creator>Pinilla, Karen</creator><creator>Dayimu, Alimu</creator><creator>Grybowicz, Louise</creator><creator>Demiris, Nikolaos</creator><creator>Harvey, Caron</creator><creator>Drewett, Lynsey M.</creator><creator>Lucey, Rebecca</creator><creator>Fulton, Alexander</creator><creator>Roberts, Anne N.</creator><creator>Worley, Joanna R.</creator><creator>Chhabra, Anita</creator><creator>Qian, Wendi</creator><creator>Vallier, Anne-Laure</creator><creator>Hardy, Richard M.</creator><creator>Chan, Steve</creator><creator>Hickish, Tamas</creator><creator>Tripathi, Devashish</creator><creator>Venkitaraman, Ramachandran</creator><creator>Persic, Mojca</creator><creator>Aslam, Shahzeena</creator><creator>Glassman, Daniel</creator><creator>Raj, Sanjay</creator><creator>Borley, Annabel</creator><creator>Braybrooke, Jeremy P.</creator><creator>Sutherland, Stephanie</creator><creator>Staples, Emma</creator><creator>Scott, Lucy C.</creator><creator>Davies, Mark</creator><creator>Palmer, Cheryl A.</creator><creator>Moody, Margaret</creator><creator>Churn, Mark J.</creator><creator>Newby, Jacqueline C.</creator><creator>Mukesh, Mukesh B.</creator><creator>Chakrabarti, Amitabha</creator><creator>Roylance, Rebecca R.</creator><creator>Schouten, Philip C.</creator><creator>Levitt, Nicola C.</creator><creator>McAdam, Karen</creator><creator>Armstrong, Anne C.</creator><creator>Copson, Ellen R.</creator><creator>McMurtry, Emma</creator><creator>Tischkowitz, Marc</creator><creator>Provenzano, Elena</creator><creator>Earl, Helena M.</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QG</scope><scope>7QL</scope><scope>7QP</scope><scope>7QR</scope><scope>7SN</scope><scope>7SS</scope><scope>7ST</scope><scope>7T5</scope><scope>7TG</scope><scope>7TK</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>KL.</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>P64</scope><scope>RC3</scope><scope>SOI</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-0688-4807</orcidid><orcidid>https://orcid.org/0000-0002-2723-0805</orcidid><orcidid>https://orcid.org/0000-0002-6226-447X</orcidid><orcidid>https://orcid.org/0000-0002-7880-0628</orcidid><orcidid>https://orcid.org/0000-0002-9899-8010</orcidid><orcidid>https://orcid.org/0000-0002-4238-3471</orcidid></search><sort><creationdate>20240530</creationdate><title>The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer</title><author>Abraham, Jean E. ; Pinilla, Karen ; Dayimu, Alimu ; Grybowicz, Louise ; Demiris, Nikolaos ; Harvey, Caron ; Drewett, Lynsey M. ; Lucey, Rebecca ; Fulton, Alexander ; Roberts, Anne N. ; Worley, Joanna R. ; Chhabra, Anita ; Qian, Wendi ; Vallier, Anne-Laure ; Hardy, Richard M. ; Chan, Steve ; Hickish, Tamas ; Tripathi, Devashish ; Venkitaraman, Ramachandran ; Persic, Mojca ; Aslam, Shahzeena ; Glassman, Daniel ; Raj, Sanjay ; Borley, Annabel ; Braybrooke, Jeremy P. ; Sutherland, Stephanie ; Staples, Emma ; Scott, Lucy C. ; Davies, Mark ; Palmer, Cheryl A. ; Moody, Margaret ; Churn, Mark J. ; Newby, Jacqueline C. ; Mukesh, Mukesh B. ; Chakrabarti, Amitabha ; Roylance, Rebecca R. ; Schouten, Philip C. ; Levitt, Nicola C. ; McAdam, Karen ; Armstrong, Anne C. ; Copson, Ellen R. ; McMurtry, Emma ; Tischkowitz, Marc ; Provenzano, Elena ; Earl, Helena M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c426t-6bbd32eb8681ac11d1ed6d5916f830404fcd1869b7be395a763e356a4d6a9f2e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>631/67/1059/602</topic><topic>631/67/1059/99</topic><topic>631/67/1347</topic><topic>Adult</topic><topic>Aged</topic><topic>Anthracycline</topic><topic>Anthracyclines - administration & dosage</topic><topic>Anthracyclines - therapeutic use</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>BRCA1 protein</topic><topic>BRCA1 Protein - genetics</topic><topic>BRCA1 Protein - metabolism</topic><topic>BRCA2 protein</topic><topic>BRCA2 Protein - genetics</topic><topic>Breast cancer</topic><topic>Carboplatin</topic><topic>Carboplatin - administration & dosage</topic><topic>Carboplatin - therapeutic use</topic><topic>Chemotherapy</topic><topic>Female</topic><topic>Germ-Line Mutation</topic><topic>Humanities and Social Sciences</topic><topic>Humans</topic><topic>Middle Aged</topic><topic>multidisciplinary</topic><topic>Neoadjuvant Therapy</topic><topic>Ovarian cancer</topic><topic>Paclitaxel</topic><topic>Paclitaxel - administration & dosage</topic><topic>Patients</topic><topic>Phthalazines - administration & dosage</topic><topic>Phthalazines - therapeutic use</topic><topic>Piperazines - administration & dosage</topic><topic>Piperazines - therapeutic use</topic><topic>Prospective Studies</topic><topic>Science</topic><topic>Science (multidisciplinary)</topic><topic>Surgery</topic><topic>Survival</topic><topic>Triple Negative Breast Neoplasms - drug therapy</topic><topic>Triple Negative Breast Neoplasms - pathology</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Abraham, Jean E.</creatorcontrib><creatorcontrib>Pinilla, Karen</creatorcontrib><creatorcontrib>Dayimu, Alimu</creatorcontrib><creatorcontrib>Grybowicz, Louise</creatorcontrib><creatorcontrib>Demiris, Nikolaos</creatorcontrib><creatorcontrib>Harvey, Caron</creatorcontrib><creatorcontrib>Drewett, Lynsey M.</creatorcontrib><creatorcontrib>Lucey, Rebecca</creatorcontrib><creatorcontrib>Fulton, Alexander</creatorcontrib><creatorcontrib>Roberts, Anne N.</creatorcontrib><creatorcontrib>Worley, Joanna R.</creatorcontrib><creatorcontrib>Chhabra, Anita</creatorcontrib><creatorcontrib>Qian, Wendi</creatorcontrib><creatorcontrib>Vallier, Anne-Laure</creatorcontrib><creatorcontrib>Hardy, Richard M.</creatorcontrib><creatorcontrib>Chan, Steve</creatorcontrib><creatorcontrib>Hickish, Tamas</creatorcontrib><creatorcontrib>Tripathi, Devashish</creatorcontrib><creatorcontrib>Venkitaraman, Ramachandran</creatorcontrib><creatorcontrib>Persic, Mojca</creatorcontrib><creatorcontrib>Aslam, Shahzeena</creatorcontrib><creatorcontrib>Glassman, Daniel</creatorcontrib><creatorcontrib>Raj, Sanjay</creatorcontrib><creatorcontrib>Borley, Annabel</creatorcontrib><creatorcontrib>Braybrooke, Jeremy P.</creatorcontrib><creatorcontrib>Sutherland, Stephanie</creatorcontrib><creatorcontrib>Staples, Emma</creatorcontrib><creatorcontrib>Scott, Lucy C.</creatorcontrib><creatorcontrib>Davies, Mark</creatorcontrib><creatorcontrib>Palmer, Cheryl A.</creatorcontrib><creatorcontrib>Moody, Margaret</creatorcontrib><creatorcontrib>Churn, Mark J.</creatorcontrib><creatorcontrib>Newby, Jacqueline C.</creatorcontrib><creatorcontrib>Mukesh, Mukesh B.</creatorcontrib><creatorcontrib>Chakrabarti, Amitabha</creatorcontrib><creatorcontrib>Roylance, Rebecca R.</creatorcontrib><creatorcontrib>Schouten, Philip C.</creatorcontrib><creatorcontrib>Levitt, Nicola C.</creatorcontrib><creatorcontrib>McAdam, Karen</creatorcontrib><creatorcontrib>Armstrong, Anne C.</creatorcontrib><creatorcontrib>Copson, Ellen R.</creatorcontrib><creatorcontrib>McMurtry, Emma</creatorcontrib><creatorcontrib>Tischkowitz, Marc</creatorcontrib><creatorcontrib>Provenzano, Elena</creatorcontrib><creatorcontrib>Earl, Helena M.</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Environment Abstracts</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>Environment Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Nature (London)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Abraham, Jean E.</au><au>Pinilla, Karen</au><au>Dayimu, Alimu</au><au>Grybowicz, Louise</au><au>Demiris, Nikolaos</au><au>Harvey, Caron</au><au>Drewett, Lynsey M.</au><au>Lucey, Rebecca</au><au>Fulton, Alexander</au><au>Roberts, Anne N.</au><au>Worley, Joanna R.</au><au>Chhabra, Anita</au><au>Qian, Wendi</au><au>Vallier, Anne-Laure</au><au>Hardy, Richard M.</au><au>Chan, Steve</au><au>Hickish, Tamas</au><au>Tripathi, Devashish</au><au>Venkitaraman, Ramachandran</au><au>Persic, Mojca</au><au>Aslam, Shahzeena</au><au>Glassman, Daniel</au><au>Raj, Sanjay</au><au>Borley, Annabel</au><au>Braybrooke, Jeremy P.</au><au>Sutherland, Stephanie</au><au>Staples, Emma</au><au>Scott, Lucy C.</au><au>Davies, Mark</au><au>Palmer, Cheryl A.</au><au>Moody, Margaret</au><au>Churn, Mark J.</au><au>Newby, Jacqueline C.</au><au>Mukesh, Mukesh B.</au><au>Chakrabarti, Amitabha</au><au>Roylance, Rebecca R.</au><au>Schouten, Philip C.</au><au>Levitt, Nicola C.</au><au>McAdam, Karen</au><au>Armstrong, Anne C.</au><au>Copson, Ellen R.</au><au>McMurtry, Emma</au><au>Tischkowitz, Marc</au><au>Provenzano, Elena</au><au>Earl, Helena M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer</atitle><jtitle>Nature (London)</jtitle><stitle>Nature</stitle><addtitle>Nature</addtitle><date>2024-05-30</date><risdate>2024</risdate><volume>629</volume><issue>8014</issue><spage>1142</spage><epage>1148</epage><pages>1142-1148</pages><issn>0028-0836</issn><issn>1476-4687</issn><eissn>1476-4687</eissn><abstract>PARTNER is a prospective, phase II–III, randomized controlled clinical trial that recruited patients with triple-negative breast cancer
1
,
2
, who were germline
BRCA
1
and
BRCA2
wild type
3
. Here we report the results of the trial. Patients (
n
= 559) were randomized on a 1:1 basis to receive neoadjuvant carboplatin–paclitaxel with or without 150 mg olaparib twice daily, on days 3 to 14, of each of four cycles (gap schedule olaparib, research arm) followed by three cycles of anthracycline-based chemotherapy before surgery. The primary end point was pathologic complete response (pCR)
4
, and secondary end points included event-free survival (EFS) and overall survival (OS)
5
. pCR was achieved in 51% of patients in the research arm and 52% in the control arm (
P
= 0.753). Estimated EFS at 36 months in the research and control arms was 80% and 79% (log-rank
P
> 0.9), respectively; OS was 90% and 87.2% (log-rank
P
= 0.8), respectively. In patients with pCR, estimated EFS at 36 months was 90%, and in those with non-pCR it was 70% (log-rank
P
< 0.001), and OS was 96% and 83% (log-rank
P
< 0.001), respectively. Neoadjuvant olaparib did not improve pCR rates, EFS or OS when added to carboplatin–paclitaxel and anthracycline-based chemotherapy in patients with triple-negative breast cancer who were germline
BRCA1
and
BRCA2
wild type. ClinicalTrials.gov ID:
NCT03150576
.
A study details the results of the PARTNER trial, a prospective, randomized controlled trial of the use of neoadjuvant olaparib with carboplatin–paclitaxel chemotherapy in patients with triple-negative breast cancer who were germline
BRCA1
and
BRCA2
wild type.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>38588696</pmid><doi>10.1038/s41586-024-07384-2</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0003-0688-4807</orcidid><orcidid>https://orcid.org/0000-0002-2723-0805</orcidid><orcidid>https://orcid.org/0000-0002-6226-447X</orcidid><orcidid>https://orcid.org/0000-0002-7880-0628</orcidid><orcidid>https://orcid.org/0000-0002-9899-8010</orcidid><orcidid>https://orcid.org/0000-0002-4238-3471</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-0836 |
| ispartof | Nature (London), 2024-05, Vol.629 (8014), p.1142-1148 |
| issn | 0028-0836 1476-4687 1476-4687 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11136660 |
| source | MEDLINE; SpringerLink Journals; Nature Journals Online |
| subjects | 631/67/1059/602 631/67/1059/99 631/67/1347 Adult Aged Anthracycline Anthracyclines - administration & dosage Anthracyclines - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use BRCA1 protein BRCA1 Protein - genetics BRCA1 Protein - metabolism BRCA2 protein BRCA2 Protein - genetics Breast cancer Carboplatin Carboplatin - administration & dosage Carboplatin - therapeutic use Chemotherapy Female Germ-Line Mutation Humanities and Social Sciences Humans Middle Aged multidisciplinary Neoadjuvant Therapy Ovarian cancer Paclitaxel Paclitaxel - administration & dosage Patients Phthalazines - administration & dosage Phthalazines - therapeutic use Piperazines - administration & dosage Piperazines - therapeutic use Prospective Studies Science Science (multidisciplinary) Surgery Survival Triple Negative Breast Neoplasms - drug therapy Triple Negative Breast Neoplasms - pathology Tumors |
| title | The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T06%3A54%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20PARTNER%20trial%20of%20neoadjuvant%20olaparib%20with%20chemotherapy%C2%A0in%20triple-negative%20breast%20cancer&rft.jtitle=Nature%20(London)&rft.au=Abraham,%20Jean%20E.&rft.date=2024-05-30&rft.volume=629&rft.issue=8014&rft.spage=1142&rft.epage=1148&rft.pages=1142-1148&rft.issn=0028-0836&rft.eissn=1476-4687&rft_id=info:doi/10.1038/s41586-024-07384-2&rft_dat=%3Cproquest_pubme%3E3035075304%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3063798873&rft_id=info:pmid/38588696&rfr_iscdi=true |